BONOMO SARA MARIA

Grassilli, E., Cerrito, M., Bonomo, S., Giovannoni, R., Conconi, D., Lavitrano, M. (2021). p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 9 [10.3389/fcell.2021.690365]. Dettaglio

Lavitrano, M., Ianzano, L., Bonomo, S., Cialdella, A., Cerrito, M., Pisano, F., et al. (2020). BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers. JOURNAL OF PATHOLOGY, 250(2), 134-147 [10.1002/path.5347]. Dettaglio

Giordano, F., Vaira, V., Cortinovis, D., Bonomo, S., Goedmakers, J., Brena, F., et al. (2019). p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 38(1) [10.1186/s13046-019-1199-7]. Dettaglio

Cerrito, M., De Giorgi, M., Pelizzoni, D., Bonomo, S., Digiacomo, N., Scagliotti, A., et al. (2018). Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. ONCOTARGET, 9(44), 27448-27459 [10.18632/oncotarget.25422]. Dettaglio

Grassilli, E., Pisano, F., Cialdella, A., Bonomo, S., Missaglia, C., Cerrito, M., et al. (2016). A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation. ONCOGENE, 35(33), 4368-4378 [10.1038/onc.2015.504]. Dettaglio